Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WU-KONG16 adjuvant sunvozertinib versus placebo in resected EGFR exon 20 insertion or PACC-mutant NSCLC
CTR20253203Phase 3Active
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Dec 2025; status: active.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253203.